Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BUSPIRONE HYDROCHLORIDE

All products: general benefit

Other products in the same Health Canada class (N05B) — coverage varies; not interchangeable

  • Lorazepam (Ativan): limited Use 481, Not a benefit

Buspirone · DIN 02447851 · 10mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.Discontinued 2026-01-12 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Buspirone · DIN 02447851 Manufacturer: Sanis Health Inc.; listing date 2016-07-28 Health Canada: Cancelled post market since 2026-01-12 · brand BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93348 · Verify on the e-Formulary ↗ (DIN 02447851)

Source record
DIN 02447851: Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447851 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93348
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-BUSPIRONE (buspirone hydrochloride) is indicated for: • short term symptomatic relief of excessive anxiety in patients with Generalized Anxiety Disorder The effectiveness of buspirone hydrochloride in long-term use (i.e. more than 4 weeks) has not been evaluated in controlled clinical trials. 1.1 Pediatrics Pediatrics (˂ 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: Buspirone has not been systematically evaluated in geriatric patients. Although it would appear from limited pharmacokinetic and clinical studies that buspirone does not behave differently in the elderly, there is little known about the effects of buspirone in this age group at doses above 30 mg/day (See 7.1.4 Geriatrics). Long-term use of pms-BUSPIRONE should be avoided in geriatric patients. Enhanced monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and Fractures; 4 .DOSAGE AND ADMINISTRATION, Dosing Considerations). https://pdf.hres.ca/dpd_pm/00072520.PDF PM date: MAR 18, 1997 Source product: PMS-BUSPIRONE; DIN 02230942; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.